Literature DB >> 11866484

Drug metabolism and drug interactions in the elderly.

C Herrlinger1, U Klotz.   

Abstract

In the elderly concomitant use of several drugs (polypharmacy) is very common. Thus, the risk for drug interactions might be increased in this population. Since most drugs are hepatically eliminated by various metabolic pathways, liver function has to be considered as an additional factor modifying drug response. This chapter focuses on the hepatic mechanisms of interactions, especially on various inhibitors and inducers of the most important cytochrome P450 isoenzymes involved in drug metabolism. In addition, age-dependent changes in liver function are addressed. Based on pharmacokinetic results with different probe drugs, some inconsistencies in this area are discussed. The most important metabolic drug-drug interactions are independent of the age of the patients. However, since elderly patients consume a greater proportional share of drugs, they represent a population at risk for interactions. Awareness of this clinical problem may help to diminish those risks. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11866484     DOI: 10.1053/bega.2001.0249

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  36 in total

Review 1.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 2.  Predicting and preventing adverse drug reactions in the very old.

Authors:  Louis Merle; Marie-Laure Laroche; Thierry Dantoine; Jean-Pierre Charmes
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

4.  The elderly--a challenge for appropriate drug treatment.

Authors:  Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-03       Impact factor: 2.953

5.  Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.

Authors:  Edoardo G Giannini; Federica Malfatti; Federica Botta; Simone Polegato; Emanuela Testa; Alessandra Fumagalli; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

6.  Statin-macrolide interaction risk: a population-based study throughout a general practice database.

Authors:  Nadia Piacentini; Gianluca Trifiró; Michele Tari; Salvatore Moretti; Vincenzo Arcoraci
Journal:  Eur J Clin Pharmacol       Date:  2005-07-26       Impact factor: 2.953

7.  Prevalence and Factors Associated with Analgesic Prescribing in Poly-Medicated Elderly Patients.

Authors:  Aymen Ali Al-Qurain; Lemlem G Gebremichael; Muhammad Suleman Khan; Desmond B Williams; Lorraine Mackenzie; Craig Phillips; Patrick Russell; Michael S Roberts; Michael D Wiese
Journal:  Drugs Aging       Date:  2020-04       Impact factor: 3.923

8.  Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.

Authors:  Kalliopi Chatzika; Katerina Manika; Paschalina Kontou; Georgia Pitsiou; Despina Papakosta; Konstantinos Zarogoulidis; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

Review 9.  Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

Authors:  Jochen Graff; Sebastian Harder
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

Review 10.  Drug-induced liver injury in the elderly.

Authors:  Jonathan G Stine; Praveen Sateesh; James H Lewis
Journal:  Curr Gastroenterol Rep       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.